scholarly article | Q13442814 |
P50 | author | Toru Hachisuga | Q89276958 |
Shintaro Yanazume | Q89841413 | ||
Satomi Aihara | Q90326437 | ||
Akira Fujishita | Q90326441 | ||
Shuichi Taniguchi | Q90326444 | ||
Hiroaki Kobayashi | Q90326449 | ||
Kimio Ushijima | Q90326451 | ||
Shin Nishio | Q54249184 | ||
P2093 | author name string | Mototsugu Shimokawa | |
Masatoshi Yokoyama | |||
Fumihiro Murakami | |||
Fumitaka Numa | |||
Naofumi Okura | |||
Kohei Kotera | |||
Naoyuki Toki | |||
P2860 | cites work | Major clinical research advances in gynecologic cancer in 2013 | Q24562146 |
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review | Q28081186 | ||
International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. | Q30317561 | ||
Antiemetics: American Society of Clinical Oncology clinical practice guideline update | Q34030613 | ||
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference | Q34121232 | ||
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. | Q35082647 | ||
Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment | Q35350242 | ||
The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo | Q35454299 | ||
Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron | Q35904224 | ||
Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic ch | Q36004950 | ||
Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer | Q36205615 | ||
Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist | Q36616499 | ||
Palonosetron as an anti-emetic and anti-nausea agent in oncology. | Q36663660 | ||
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial | Q36729483 | ||
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy | Q37111164 | ||
Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy | Q37375653 | ||
Advances in the management of recurrent endometrial cancer | Q38114284 | ||
Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials | Q38192940 | ||
Review of Recommended Treatment of Uterine Carcinosarcoma | Q38587635 | ||
Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin | Q39010204 | ||
Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis | Q39453505 | ||
The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy | Q40782212 | ||
Quality of life consequences of chemotherapy-induced emesis | Q41080940 | ||
Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting | Q41116408 | ||
The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro | Q41969040 | ||
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemothe | Q43191959 | ||
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron | Q44592616 | ||
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron | Q44667127 | ||
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study | Q44754098 | ||
Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects | Q44854827 | ||
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial | Q46168564 | ||
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy | Q46448765 | ||
NCCN Guidelines Insights: Antiemesis, Version 2.2017. | Q47572768 | ||
Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study | Q47870600 | ||
Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. | Q50980250 | ||
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. | Q52836736 | ||
Measuring chemotherapy-induced nausea and emesis. | Q53379104 | ||
Validation and Psychometric Assessment of a Short Clinical Scale to Measure Chemotherapy-Induced Nausea and Vomiting: The MASCC Antiemesis Tool | Q60732056 | ||
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy | Q83967286 | ||
The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study | Q87631928 | ||
P433 | issue | 5 | |
P921 | main subject | gynecologic oncology | Q5625186 |
(3aS)-palonosetron | Q419841 | ||
dexamethasone | Q422252 | ||
chemotherapy | Q974135 | ||
P304 | page(s) | e77 | |
P577 | publication date | 2018-05-15 | |
P1433 | published in | Journal of gynecologic oncology | Q26842232 |
P1476 | title | Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131) | |
P478 | volume | 29 |